TY - JOUR
T1 - Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles
AU - Peer, Dan
N1 - Funding Information:
Dan Peer wishes to thank Ms. Varda Wexler for her help with the graphics and illustrations and the Peer laboratory members for helpful discussions. This work was supported in part by grants from the Marie Curie IRG-FP7 of the European Union , Lewis Family Trust , Israel Science Foundation ( Award #181/10 ), The MAGNET program of the Israeli OCS , the Kenneth Rainin Foundation , the Israeli Centers of Research Excellence (I-CORE) , Gene Regulation in Complex Human Disease, Center No 41/11 and by the FTA: Nanomedicine for Personalized Theranostics awarded to D.P.
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/12
Y1 - 2012/12
N2 - Lipid-based nanoparticles (LNPs) such as liposomes, micelles, and hybrid systems (e.g. lipid-polymer) are prominent delivery vehicles that already made an impact on the lives of millions around the globe. A common denominator of all these LNP-based platforms is to deliver drugs into specific tissues or cells in a pathological setting with minimal adverse effects on bystander cells. All these platforms must be compatible to the physiological environment and prevent undesirable interactions with the immune system. Avoiding immune stimulation or suppression is an important consideration when developing new strategies in drug and gene delivery, whereas in adjuvants for vaccine therapies, immune activation is desired. Therefore, profound understanding of how LNPs elicit immune responses is essential for the optimization of these systems for various biomedical applications. Herein, I describe general concepts of the immune system and the interaction of subsets of leukocytes with LNPs. Finally, I detail the different immune toxicities reported and propose ways to manipulate leukocytes' functions using LNPs.
AB - Lipid-based nanoparticles (LNPs) such as liposomes, micelles, and hybrid systems (e.g. lipid-polymer) are prominent delivery vehicles that already made an impact on the lives of millions around the globe. A common denominator of all these LNP-based platforms is to deliver drugs into specific tissues or cells in a pathological setting with minimal adverse effects on bystander cells. All these platforms must be compatible to the physiological environment and prevent undesirable interactions with the immune system. Avoiding immune stimulation or suppression is an important consideration when developing new strategies in drug and gene delivery, whereas in adjuvants for vaccine therapies, immune activation is desired. Therefore, profound understanding of how LNPs elicit immune responses is essential for the optimization of these systems for various biomedical applications. Herein, I describe general concepts of the immune system and the interaction of subsets of leukocytes with LNPs. Finally, I detail the different immune toxicities reported and propose ways to manipulate leukocytes' functions using LNPs.
KW - Antigen-presenting cells
KW - Immune response
KW - Leukocytes
KW - Lipid-based nanoparticles
KW - Liposomes
KW - RNAi
KW - T cells
UR - http://www.scopus.com/inward/record.url?scp=84869200994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869200994&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2012.06.013
DO - 10.1016/j.addr.2012.06.013
M3 - Review article
C2 - 22820531
AN - SCOPUS:84869200994
SN - 0169-409X
VL - 64
SP - 1738
EP - 1748
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 15
ER -